China’s Sinovac Covid-19 vaccine yesterday, June 1st, has been officially validated by the World Health Organization (WHO) for emergency use, marking the second Chinese vaccine to receive the green light from the WHO, after Sinopharm.

The emergency use approval means that the vaccine “meets international standards for safety, efficacy, and manufacturing”, according to the WHO statement. It will also be used in the Covax program, which aims to contribute fair access to the vaccines.

The Sinovac-Corovac vaccine has been deployed in several countries around the world, including Thailand, prior to the approval. It is recommended for adults over 18 years old, with a second dose two to four weeks later.

“Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe Covid-19 and hospitalization in 100% of the studied population,” the WHO said.

A study in a Brazilian research institute of a small city called Serrana indicated an 80% drop in Covid symptomatic cases, an 86% decrease in hospitalizations, and a 95% drop in deaths after a full inoculation of almost all of its adults with the Sinovac vaccine.

The preliminary results in the Brazilian study have also proved that the vaccines created an immunity barrier for the community, according to the study and the WHO.




フォローしてください フェイスブック, ツイッター, グーグルニュース, インスタグラム, チクトク, ユーチューブ, Pinterest(ピンタレスト, フリップボード, パーラーまたは タンブラー


Facebookグループのディスカッションに参加しましょう https://www.facebook.com/groups/438849630140035/ または下のコメント欄にご記入ください。

広告掲載をご希望の方や、ビジネス、イベント、チャリティ、スポーツイベントなどのプロモーションに関するお問い合わせはこちらから。メールでお問い合わせください。 [email protected]

一般的なニュースチップ、プレスリリース、質問、コメントなどをお持ちですか?私たちは、SEOの提案に興味はありません。私達にメールを送ってください [email protected]

5 (1 投票)